COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
DelveInsight’s, “Mantle Cell Lymphoma Pipeline Insight, 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including Mantle Cell Lymphoma clinical trials and nonclinical stage products. It also covers the Mantle Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Mantle Cell Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Mantle Cell Lymphoma NDA approvals (if any), and product development activities comprising the technology, Mantle Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Mantle Cell Lymphoma Pipeline Report
To explore more information on the latest breakthroughs in the Mantle Cell Lymphoma Pipeline treatment landscape of the report, click here @ Mantle Cell Lymphoma Pipeline Outlook
Mantle Cell Lymphoma Overview
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) usually identified by a translocation of the CCND1 gene. The variety of morphologic variants may make this a challenging diagnosis, although most cases are uncomplicated. It typically follows an aggressive clinical course, although an indolent leukemia variant has been described.
Mantle Cell Lymphoma Emerging Drugs Profile
Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis. Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S. Currently the product is in Phase III for mantle cell lymphoma.
Daratumumab is a first-in-class3 biologic targeting CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage.4 Daratumumab is believed to induce tumour cell death through multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as well as through apoptosis, in which a series of molecular steps in a cell lead to its death. Currently the product is in Phase II for the treatment of Mantle Cell Lymphoma.
For further information, refer to the detailed Mantle Cell Lymphoma Unmet Needs, Mantle Cell Lymphoma Market Drivers, and Market Barriers, click here for Mantle Cell Lymphoma Ongoing Clinical Trial Analysis
Mantle Cell Lymphoma Pipeline Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies Mantle Cell Lymphoma. The companies which have their Mantle Cell Lymphoma drug candidates in the most advanced stage, i.e phase III include Abbvie
Mantle Cell Lymphoma Phases
Request a sample and discover the recent advances in Mantle Cell Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Mantle Cell Lymphoma Treatment Landscape
Scope of the Mantle Cell Lymphoma Pipeline Insight Report
Dive deep into rich insights for drugs for Mantle Cell Lymphoma Market Drivers and Mantle Cell Lymphoma Market Barriers, click here @ Mantle Cell Lymphoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Mantle Cell Lymphoma Mergers and acquisitions, Mantle Cell Lymphoma licensing activities @ Mantle Cell Lymphoma Emerging Drugs, and Recent Trends
List of Top Selling Market Research Reports in 2023
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com